Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for ... Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. Show more
WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.022249 | 9.77119016249 | 0.2277 | 0.2639 | 0.1927 | 19814133 | 0.21887687 | CS |
4 | 0.048949 | 24.3527363184 | 0.201 | 0.438934 | 0.1539 | 23577449 | 0.20994398 | CS |
12 | 0.029949 | 13.6131818182 | 0.22 | 0.438934 | 0.1539 | 9013216 | 0.22437177 | CS |
26 | -0.189951 | -43.1804955672 | 0.4399 | 0.48 | 0.1539 | 4642514 | 0.23809688 | CS |
52 | -1.060051 | -80.9199236641 | 1.31 | 1.53 | 0.1281 | 9628022 | 0.57806894 | CS |
156 | -23.750051 | -98.9585458333 | 24 | 24.5985 | 0.1281 | 3508499 | 1.44241258 | CS |
260 | -62.900051 | -99.6041979414 | 63.15 | 78.3 | 0.1281 | 2697469 | 12.43470596 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.